Detailed Narrative
Q3 FY26 Performance Overview
Camlin Fine Sciences reported a Q3 FY26 turnover of ₹572 crores, marking a 6% year-on-year increase, though it was flat quarter-on-quarter. The EBITDA margin for the quarter compressed to 6.7% from 7.3% in the previous quarter, primarily due to challenges in the Straights business and fixed cost absorption issues in Vanillin. The Gross Margin for Q3 FY26 stood at 45.8%, impacted by declining realizations in the Straights segment.
Segmental Performance and Outlook
The Blends business demonstrated strong growth, increasing by 11% year-on-year and 13% quarter-on-quarter, achieving ₹271 crores in revenue. The recent acquisition of Vinpai contributed approximately ₹13 crores to this segment in Q3 FY26. Conversely, the Straights business saw a decline to ₹80 crores from ₹87 crores, impacted by falling prices and intense competition. Vanillin sales for the quarter were 490 tons, generating ₹55 crores at an average realization of $12.5.
Vanillin Strategy and Tariff Impact
The company strategically delayed selling approximately 200 tons of Vanillin in Q3 to benefit from an anticipated reduction in US tariffs. Management expects the US Vanillin realization to increase to $14-$14.5 from $12.5 once the tariff reduces to 25%, and further to $15.5 if it drops to 18%. For FY27, the company targets a significant Vanillin volume of 4,000 metric tons, a 50-60% increase from current levels, with 60% of sales directed to the US and 40% to Europe.
Acquisition Integration and Growth Targets
The integration of Vitafor and Vinpai is progressing, with Vitafor targeting a topline of €17-18 million in FY27, representing 40-50% growth from its current €12-13 million. Vinpai is also expected to achieve 40-50% growth in FY27 from its €11 million topline. These acquisitions are central to the company's strategy for expanding its Blends business and market reach globally, with new product launches in various geographies including the US, Mexico, Brazil, and India.
Exceptional Items and Business Discontinuation
The quarter saw several exceptional item📎s, including ₹3.69 crores for Vinpai acquisition-related costs and a ₹2.25 crores provision for statutory bonuses. The company also reported ₹9 crores from discontinued European business and ₹1 crore from Chinese operations in Q3. Management anticipates the liquidation of these entities by the end of the financial year, which will cease the associated cash bleed of ₹7-8 crores per quarter for Europe and ₹1 crore for China, although no money realization is expected from these liquidations.
Brazil Fire Incident and Insurance
A fire incident at a blending unit in Brazil resulted in a total book value loss of ₹32.7 crores, comprising ₹28 crores in inventory and ₹4.5 crores in machinery and equipment. The company is adequately insured, but the unit is currently unusable. The full impact and insurance recovery timeline are pending the completion of surveys, which are expected to take 3-4 weeks, making the immediate operational and financial impact uncertain.
Financial Guidance for FY27 and FY28
Camlin Fine Sciences provided revenue guidance of ₹2,200 crores for FY27 and ₹2,400 crores for FY28. The company also projects an improvement in Gross Margin to 46-47% and EBITDA Margin to 12-14% for FY27, driven by higher Vanillin realizations and growth in the Blends segment. Annual maintenance capex is estimated at ₹40-50 crores, with no new major capex plans currently approved, indicating a focus on organic growth and integration of recent acquisitions.